Compare CVS Health Corp (CVS) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs SOLAI Limited — how do they compare? CVS Health Corp trades at $106.11 (market cap $135.48B), while SOLAI Limited trades at $3.14 (market cap $14.09M). The key difference: CVS Health Corp is far larger — about 9615.3× SOLAI Limited's market cap, and CVS Health Corp pays a 2.51% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| CVS | SLAI | |
|---|---|---|
Market Cap | $135.48B | $14.09M |
Sector | Health | Technology |
52-Week High | $106.18 | $30.66 |
52-Week Low | $58.75 | $2.74 |
Enterprise Value | $202.02B | $13.72M |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
SLAI trades at $3.24, down 2.99% today, with a bullish technical signal supported by moving averages. The company shows concerning fundamentals with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Recent developments include the acquisition of a 51% stake in NEURALAND and the launch of Solode Neo AI device. The stock faces NYSE listing standard concerns but shows improved revenue guidance for 2026.
The outlook remains challenged by persistent losses and regulatory risks, though recent acquisitions and product launches offer potential growth catalysts. Investors face significant execution risk amid negative profitability metrics, while technical indicators suggest near-term price support around $3 with resistance at $4.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
